Literature DB >> 16035475

K/DOQI gets to the heart of managing dyslipidemias in patients with CKD.

Deborah Benner1.   

Abstract

There is a wealth of data in the general population regarding interventions to reduce cardiovascular risk. Unfortunately, most of these studies exclude patients with chronic kidney disease. As a result, the lack of CKD specific data has resulted in a lack of attention and intervention. With the epidemic levels of cardiovascular disease in patients on dialysis, the NKF has established these K/DOQI guidelines in an effort to get to the "heart" of dyslipidemias and ultimately to assist the health care team in their effort to improve CKD patient outcomes. In addition, the National Kidney Foundation currently has draft K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in the public review process. These new guidelines will elaborate on areas not covered in the dyslipidemia guidelines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16035475

Source DB:  PubMed          Journal:  Nephrol Nurs J        ISSN: 1526-744X            Impact factor:   0.959


  2 in total

1.  Evolving pandemic diabetic nephropathy.

Authors:  Eli A Friedman
Journal:  Rambam Maimonides Med J       Date:  2010-07-02

2.  Combinational Use of Antiplatelet Medication Sarpogrelate with Therapeutic Drug Rosuvastatin in Treating High-Cholesterol Diet-Induced Chronic Kidney Disease in ApoE-Deficient Mice.

Authors:  Jingyi Xu; Zuowei Pei; Meng Yu; Xiang Li; Lu Wang; Yichen Lin; Xinyan Chen; Xiaodan Liu
Journal:  Biomed Res Int       Date:  2020-09-26       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.